Takeda Pharmaceuticals has named Julie Kim as the first woman to lead the 244-year-old Japanese drugmaker, a rarity in senior ...
Julie Kim has been running Takeda’s US operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval.
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...
Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.
Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...